GPR137C and prostate adenocarcinoma: Furthermore, acetaminophen, valproic acid, and MPIX-(PEG) 2-G (PNA)-d-Lys-d-Lys (mPG) probably could be utilized to target GPR137C to inhibit the development of PRAD in patients.